Pemetrexed for the first-line treatment of non-small-cell lung cancer

Review decision December 2014 information

Appendix A GE decision paper December 2014

Appendix A GE decision paper December 2014 (PDF 496 KB)

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Review Proposal October 2014 information

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Appendix A - provisional matrix of stakeholders

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Appendix A - provisional matrix of stakeholders (PDF 100 KB)

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Appendix B - proposal paper presented to the institute's guidance executive

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Appendix B - proposal paper presented to the institute's guidance executive (PDF 365 KB)

TA181 Lung cancer (non-small cell, first line treatment) - pemetrexed: review update - January 2012 information

Review update - May 2011 information

Lung cancer (non-small-cell, first line treatment) - pemetrexed: final appraisal determination  information

Lung cancer (non-small-cell, first line treatment) - pemetrexed: final appraisal determination

Lung cancer (non-small-cell, first line treatment) - pemetrexed: final appraisal determination (PDF 122 KB)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 46 KB)

Consultee and commentator comments on the ACD

Eli Lilly & Co

Eli Lilly & Co (PDF 457 KB)

British Thoracic Oncology Group

British Thoracic Oncology Group (PDF 13 KB)

British Thoracic Society

British Thoracic Society (PDF 25 KB)

Roy Castle Lung Cancer Foundation

Roy Castle Lung Cancer Foundation (PDF 41 KB)

Royal College of Nursing

Royal College of Nursing (PDF 22 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 70 KB)

Department of Health

Department of Health (PDF 8 KB)

Sanofi-Aventis

Sanofi-Aventis (PDF 9.6 KB)

ERG Addendum (CiC information)

Lung cancer (non-small-cell, first line treatment) - pemetrexed: appraisal consultation

Lung cancer (non-small-cell, first line treatment) - pemetrexed: appraisal consultation document information

Evidence considered

Pre-meeting briefing

Pre-meeting briefing (PDF 159 KB)

Lung cancer (non-small-cell, first line treatment) - pemetrexed: evidence Review Group report

Lung cancer (non-small-cell, first line treatment) - pemetrexed: evidence Review Group report (PDF 650 KB)

Non-manufacturer submissions

British Thoracic Society

British Thoracic Society (PDF 27 KB)

The Royal College of Nursing

The Royal College of Nursing (PDF 25 KB)

Eli Lilly and Co.

Eli Lilly and Co. (PDF 1.06 MB)

Expert written personal statements

Ms Catherine Docherty

Ms Catherine Docherty (PDF 17 KB)

Professor David Ferry

Professor David Ferry (PDF 56 KB)

Dr Jesme Fox

Lung cancer (non-small-cell, first line treatment) - pemetrexed: responses to scope consultation

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Final Matrix

Lung cancer (non-small-cell, first line treatment) - pemetrexed: Final Scope